Sagimet Biosciences Presented Data From FASCINATE-2 Phase 2B Trial Of Denifanstat Versus Placebo In Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis Patients At The European Association For The Study Of The Liver Congress
Portfolio Pulse from Benzinga Newsdesk
Sagimet Biosciences presented promising data from its FASCINATE-2 Phase 2B trial of Denifanstat at the European Association for the Study of the Liver Congress. The drug achieved statistically significant results in improving liver fibrosis and was generally well tolerated.
June 06, 2024 | 9:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sagimet Biosciences' Denifanstat achieved statistically significant results in improving liver fibrosis in MASH patients, meeting FDA draft guidance endpoints. The drug was also well tolerated, indicating strong potential for future approval and market success.
The positive results from the Phase 2B trial, including meeting FDA draft guidance endpoints and showing good tolerance, suggest a strong potential for Denifanstat's future approval and market success. This is likely to boost investor confidence and positively impact SGMT's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100